AI Consensus Investment Thesis
AZN: AstraZeneca Stock Price, Analysis & Forecast: 1 Year and 5 Year Targets
AstraZeneca: 1-Year and 5-Year Forecast Outlook and Rating
AstraZeneca (AZN) has an immediate No Action - Keep Monitoring consensus AI recommendation, based on 14 AI analysts.
The 1-year target is 13,257 GBX for , with +5.06% expected return (+6.88% including net dividends) and a NEUTRAL rating.
The 5-year target is 17,943 GBX for , with +42.20% expected return (+55.93% including net dividends) and a BUY rating.
Latest available market price: GBX 12,618, as of 20 Oct 2026.
Dividend calculation details
Calculated net annual dividend yield: 1.89%. As of 2026-10-20.
Gross TTM: 1.89% · Two-year annualized gross: 1.92%.
Tax withholding assumption: 0% (GB). One-off special payments are excluded.
Original published assumption: 2.1% per year.
Return estimates compound the net annual yield at a constant rate over the stated return horizon (the remaining time to the fixed target date for current returns): (1 + price return) × (1 + net annual yield)years − 1.
Targets retain their original publication dates. Returns use the dated market close and the time remaining to each fixed target date. Current ratings also require fresh quotes and analysis, with more than 90 days remaining. Past targets have no forward return. Eligibility checked .
AstraZeneca Flagship Insight
Biopharma Pipeline Replacement Velocity Collides With Severe Statutory Pricing Pressures
Consensus reflects sharp divergence between headline revenue targets and statutory cash conversion. Robust oncology expansion and rare-disease durability offset imminent Farxiga patent cliffs, but elevated clinical capital intensity and sovereign price negotiations constrain multiple expansion, anchoring an earnings-led rather than valuation-driven trajectory.
How were the Investment Thesis and Forecasts created?
14 AI advisors, guided by 9 analytical frameworks, contribute to the deep analysis by iPulse AI Engine.
Universal Investor (Polymath)
Warren Buffett (Value Purist)
Superintelligence (Anthropologist)
J.P. Morgan (Titan)
Sherlock Holmes (Whistleblower)
Michael Burry (Vulture)
Elon Musk (Visionary)
Machiavelli (Insider)
Ray Dalio (Strategist)
Ran across these frontier AI models
Google Gemini 3.8 Flash
Anthropic Claude Opus 5
OpenAI GPT-6 Astra
Latest published deep-analysis batch. Audit published forecasts in full transparency
AstraZeneca: forecast questions
What is AstraZeneca (AZN)'s 1-year price forecast?
AstraZeneca's 1-year target is 13,257 GBX for Sept 2027. The current AI rating is NEUTRAL. The expected return from the recorded close is +5.06%, or +6.88% modeled return including net dividends. Latest available market price: GBX 12,618, as of 20 Oct 2026. The target date is fixed; this is not a new rolling forecast.
What is AstraZeneca (AZN)'s 5-year price forecast?
AstraZeneca's 5-year target is 17,943 GBX for Sept 2031. The current AI rating is BUY. The expected return from the recorded close is +42.20%, or +55.93% modeled return including net dividends. Latest available market price: GBX 12,618, as of 20 Oct 2026. The target date is fixed; this is not a new rolling forecast.
What is the return basis?
Latest available market price: GBX 12,618, as of 20 Oct 2026. These are model projections, not guaranteed future prices.
How can I compare the AI opinions and audit past AstraZeneca forecasts?
14 AI analysts contribute to this publication. AI Opinions shows individual advisor forecasts and reasoning. Forecast History preserves earlier published batches; their figures describe their original publication, not today's outlook.
How does an AI-generated forecast for AstraZeneca differ from Wall Street analyst consensus?
Wall Street consensus aggregates estimates from human analysts. For listed companies, these typically include brokerage price targets, earnings forecasts and ratings. iPulse AI's forecast for AstraZeneca is a separate AI consensus generated through its own research workflow. Different inputs, forecast dates, assumptions and weighting can therefore produce different targets.
We believe the era of investment research conducted only by human analysts is drawing to a close. Frontier models increasingly match or exceed expert work on selected professional benchmarks, including evaluations covering financial analysis. Research on multi-model synthesis also shows that combining model responses can improve on a single model's output in the tasks studied.
iPulse AI generates transparent investment research and market forecasts using a swarm of AI configurations, analytical frameworks and frontier models. The workflow applies multiple verification, challenge and synthesis layers, with selective editorial review under Russlan Ramdowar, Editor-in-Chief. Published assumptions, disagreements and past forecasts remain available so readers can inspect the reasoning and audit outcomes.
For a research cycle covering 426 assets with 14 perspectives per asset, our internal workload model estimates approximately 114,000 hours of traditional analyst work. It assumes 16 hours per individual research report, 28 hours per consensus for synthesis and validation, plus shared data preparation. Parallel AI execution allows a deep-analysis cycle across hundreds of assets to complete in up to one day. The human-hours figure is an illustrative workload estimate, rather than measured time savings. Our research methodology explains the automated workflow.
AstraZeneca: Investment Thesis Summary
Dotted terms link to the glossary; hover or focus for a preview. Browse technical terms
If you invest GBX 10,000 in AstraZeneca at the latest market close (20 Oct 2026): GBX 15,593 by Sept 2031.
Returns use the same dated market close, fixed targets and remaining dividend period as the forecast table.
Benchmark comparison requires matching dated price and currency inputs.
* Return is calculated incl. 1.9% net dividend yield for AstraZeneca.
AstraZeneca functions as an industrial-scale biopharmaceutical replacement engine rather than a passive defensive bond proxy. The base-case economic argument centers on whether commercial scaling across Daiichi Sankyo-partnered antibody-drug conjugates, respiratory biologics, and rare-disease franchises can outpace mechanical generic erosion from Farxiga and maturing oncology blockbusters. While top-line revenues track toward high-seventy-billion thresholds by 2030, free cash flow conversion will lag adjusted operating figures due to persistent capital absorption across clinical trials and onshore manufacturing buildouts. Valuation sensitivity remains tightly tethered to discount rates: in an environment of elevated sovereign yields, an entry multiple above twenty-five times trailing earnings limits multiple-driven rerating. The investment case rests on mid-to-high single-digit revenue expansion translating into low-double-digit core earnings growth.
Key insights
- Partnered oncology assets deliver gross margin expansion, but shared licensing economics mean top-line blockbuster growth does not fully convert into distributable equity cash flow.
- High-barrier rare-disease therapies provide vital cash flow inelasticity, effectively subsidizing an annual research and development capital intensity exceeding twenty-three percent of revenue.
- Sovereign price controls and Medicare negotiations permanently compress late-cycle tail margins, shifting the terminal valuation basis toward volume delivery over pricing power.
AstraZeneca: 5 Year Consensus Forecast
20 quarterly price targets, returns and rationale, with advisor range and benchmark
Forward returns are updated using the latest market close price of GBX 12,618, as of 20 Oct 2026.
Dividend calculation details
Calculated net annual dividend yield: 1.89%. As of 2026-10-20.
Gross TTM: 1.89% · Two-year annualized gross: 1.92%.
Tax withholding assumption: 0% (GB). One-off special payments are excluded.
Original published assumption: 2.1% per year.
Return estimates compound the net annual yield at a constant rate over the stated return horizon (the remaining time to the fixed target date for current returns): (1 + price return) × (1 + net annual yield)years − 1.
The consensus target follows an expert-weighted price path synthesized from 14 AI advisor opinions. See Opinion weights and rationale for the exact allocation and reasoning.
Forecast methodology and reference values
Published targets are anchored on 18 Sept 2026 at GBX 12,500. Original quarter-to-quarter target changes are retained. Forward returns use the remaining time to each fixed target date.
The pessimistic and optimistic advisor base cases are the lowest and highest published advisor base-case targets for each quarter. The advisor at either extreme can change between quarters. Benchmark values are in USD; FX values are exchange rates.
Scroll the table horizontally to read every column.
| Quarter | Evidence-Weighted Consensus Price Path | Individual Advisor Range & Reference Forecasts | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Consensus target (GBX) | Forecast quarter-to-quarter price change | Forward price return | Forward return incl. net dividends | Forecast rationale | Pessimistic Advisor Base Case (GBX) | Optimistic Advisor Base Case (GBX) | S&P 500 benchmark (USD) | FX (GBP/USD) | |
| GBX 12,652 | +1.21% | +0.27% | +0.57% | Oncology volume expansion and rare-disease cash conversion counterbalance initial Farxiga pricing concessions. Defensive institutional rotation supports steady equity accumulation, though elevated research outlays and macro discount rates keep quarterly multiple appreciation measured. | GBX 12,125 | GBX 13,125 | $750 | 1.32 | |
| GBX 12,866 | +1.69% | +1.97% | +2.75% | Full-year financial reporting confirms double-digit core earnings progression alongside initial tozorakimab regulatory filings. Strong commercial uptake in breast and lung cancer indications offsets localized emerging-market pricing headwinds, sustaining positive share performance. | GBX 11,640 | GBX 13,650 | $736 | 1.31 | |
| GBX 13,089 | +1.73% | +3.73% | +5.03% | Expanding commercial contributions from newly approved therapies accelerate top-line replacement. However, US statutory pricing negotiations and European generic competition on legacy primary-care medicines impose modest gross margin friction, moderating intermediate quarterly gains. | GBX 11,407 | GBX 14,060 | $743 | 1.31 | |
| GBX 13,257 | +1.29% | +5.06% | +6.88% | Congress presentations demonstrate sustained clinical efficacy across pivotal oncology pipelines. High-barrier rare-disease therapies generate resilient cash flows, insulating group operating profits from macroeconomic consolidation and supporting steady institutional sponsorship. | GBX 11,521 | GBX 14,481 | $755 | 1.31 | |
| GBX 13,601 | +2.59% | +7.79% | +10.16% | Commercial rollouts of respiratory biologics and expanding antibody-drug conjugate indications drive volume growth. Cash generation comfortably absorbs heavy Phase III clinical trial commitments, reassuring allocators of underlying earnings durability into year-end. | GBX 11,291 | GBX 14,916 | $776 | 1.31 | |
| GBX 13,789 | +1.38% | +9.28% | +12.21% | Annual financial disclosures validate operating leverage expansion despite peak Farxiga patent-loss headwinds. Solid cash conversion supports dividend progression, though election-year drug pricing rhetoric in major Western markets prevents substantive multiple expansion. | GBX 11,404 | GBX 15,065 | $787 | 1.31 | |
| GBX 14,091 | +2.19% | +11.67% | +15.21% | Global label expansions for earlier-line solid tumor regimens broaden addressable patient populations. Incremental gross profit conversion outpaces fixed infrastructure cost growth, driving fundamental earnings upgrades across major international brokerages. | GBX 11,632 | GBX 15,666 | $803 | 1.31 | |
| GBX 14,377 | +2.03% | +13.94% | +18.11% | Late-stage cardiometabolic and bispecific pipeline readouts reinforce the medium-term replacement trajectory. Defensive healthcare inflows and easing monetary policy discount rates provide valuation support, maintaining measured quarterly price appreciation. | GBX 11,632 | GBX 16,136 | $812 | 1.32 | |
| GBX 14,695 | +2.21% | +16.46% | +21.28% | Manufacturing efficiencies across dedicated biologics facilities lower unit costs, bolstering operating margins. Positive clinical milestone deliveries cushion residual pricing drag, driving disciplined institutional positioning across high-quality pharmaceutical defensives. | GBX 11,748 | GBX 16,620 | $839 | 1.31 | |
| GBX 14,907 | +1.44% | +18.14% | +23.60% | Full-year results demonstrate that top-line growth has overcome legacy patent cliffs, with group revenues expanding solidly. Free cash flow generation improves as peak facility capital expenditures begin moderating, supporting equity gains. | GBX 11,983 | GBX 16,952 | $851 | 1.31 | |
| GBX 15,240 | +2.23% | +20.78% | +26.96% | Specialty oncology scaling drives operating margins higher, but approaching exclusivity horizons on older targeted biologics temper multiple expansion. The market balances accelerating cash generation against mid-horizon therapeutic life-cycle renewal obligations. | GBX 12,223 | GBX 17,631 | $872 | 1.31 | |
| GBX 15,521 | +1.84% | +23.01% | +29.92% | Diversified commercial demand across respiratory, rare-disease, and targeted oncology segments maintains steady volume momentum. Inelastic healthcare spending insulates operating cash generation from wider European economic deceleration, sustaining modest price progress. | GBX 12,345 | GBX 17,983 | $886 | 1.31 | |
| GBX 15,929 | +2.63% | +26.24% | +33.96% | Approaching long-range operational milestones, revenue visibility improves substantially. Maturing launch portfolios generate dependable operating cash flows, enabling balance-sheet deleveraging and funding selective pipeline licensing without equity dilution. | GBX 12,592 | GBX 18,523 | $910 | 1.32 | |
| GBX 16,174 | +1.54% | +28.18% | +36.65% | Annual reporting confirms total group revenues approaching landmark thresholds, validating long-term corporate execution. While statutory payer discounting caps terminal margins, core earnings per share expansion delivers reliable equity support. | GBX 12,844 | GBX 18,893 | $916 | 1.32 | |
| GBX 16,524 | +2.17% | +30.96% | +40.27% | Commercial maturation of next-generation oncology biologics drives operating cash flows to cyclical highs. Stable balance-sheet metrics allow management to broaden shareholder distributions, preserving defensive holding patterns across institutional registers. | GBX 12,972 | GBX 19,460 | $937 | 1.32 | |
| GBX 16,809 | +1.72% | +33.21% | +43.36% | Share price consolidation reflects a balanced market weighing substantial multi-year earnings gains against scheduled patent transitions on legacy oncology blockbusters. Non-cyclical patient demand establishes a firm valuation floor. | GBX 13,232 | GBX 19,849 | $947 | 1.32 | |
| GBX 17,118 | +1.84% | +35.66% | +46.68% | Closing out the decade, scaled biologic manufacturing and expanded global distribution cement market leadership. High cash conversion supports capital returns, delivering modest end-of-year price appreciation anchored in realized operating profits. | GBX 13,364 | GBX 20,246 | $970 | 1.32 | |
| GBX 17,396 | +1.62% | +37.87% | +49.75% | Full-year disclosures confirm structural execution across twenty commercial blockbusters. While top-line growth settles into a mature low-double-digit cadence, strong cash generation preserves fundamental valuation multiples against sovereign debt yields. | GBX 13,498 | GBX 20,449 | $980 | 1.32 | |
| GBX 17,650 | +1.46% | +39.88% | +52.66% | Early commercialization of next-generation modalities refreshes pipeline durability beyond mature product cliffs. Steady operating margins and dependable dividend accruals provide resilient equity returns during broader macroeconomic rotation. | GBX 13,510 | GBX 20,858 | $1,000 | 1.32 | |
| GBX 17,943 | +1.66% | +42.20% | +55.93% | The five-year forecast concludes with the enterprise established as a high-barrier biopharmaceutical cash compounder. Normalized earnings yield, robust therapeutic moats, and self-funding innovation justify a firm valuation baseline. | GBX 13,633 | GBX 21,275 | $1,012 | 1.32 | |
Show remaining 18 quartersShow first 2 quarters only
All 20 quarters are displayed in the table above.
AstraZeneca Stock Analysis & Scenarios Deep Dive
AstraZeneca: Alpha Gap & Repricing Catalysts
Market Narrative
What does the market currently expect? Outside market sentiment treats AstraZeneca as a premier European pharmaceutical compounder with visible top-line momentum, broadly endorsing management's aspirational eighty-billion-dollar 2030 revenue roadmap. Prevailing consensus relies on continuous oncology market share gains and rare-disease durability, assuming these high-margin pillars will effortlessly neutralize impending Farxiga patent cliffs, Chinese volume-based procurement cuts, and statutory Medicare price concessions.
Alpha Gap
What is the biggest difference between market expectations and our AI forecasts? The crowd underestimates structural friction while overestimating intermediate cash conversion, establishing that shares are fairly priced to modestly underpriced on earnings compounding rather than valuation rescue. Market consensus erroneously conflates gross top-line replacement with net distributable cash flows, overlooking that shared partner economics, capital-intensive manufacturing, and statutory price caps suppress cash margins. The analytical edge lies in recognizing that quality volume growth will drive attractive long-term owner earnings once generic headwinds trough.
Repricing Catalyst
What could make the market recognize and close that gap? Convergence requires consecutive reporting periods in 2027 demonstrating that core operating margin expansion and new launch volumes outpace Farxiga generic erosion. Pivotal Phase III readouts and regulatory approvals for tozorakimab in respiratory disease and datopotamab deruxtecan in lung cancer represent the primary operational triggers. Visible free cash flow conversion improvements will force sell-side models to de-risk medium-term cash forecasts.
AstraZeneca: Sentiment and Timing
What do sentiment, volatility, and the market-recognition cycle suggest about the thesis timing?
- Greed and Fear Sentiment
- Balanced
- Volatility Regime
- Moderate
- Convergence Cycle Position
- Growing Awareness
Sentiment assessments diverge between confidence in pipeline replacement velocity and caution regarding multi-year patent cliffs. While operational compounder views anticipate valuation stability, skeptical models warn that multiple compression will persist until generic erosion is fully absorbed.
Macro Regime Fit
Does the current market environment support the thesis? The prevailing macro regime of higher-for-longer benchmark yields and persistent cost inflation presents a mixed backdrop. Elevated discount rates compress valuation multiples on long-duration clinical pipelines and raise debt refinancing expenses. However, non-cyclical, price-inelastic demand for vital oncology and rare-disease therapies provides exceptional revenue insulation, positioning the company as a defensive compounder during stagflationary periods.
Advisor Disagreement
What do our AI Advisors disagree about most? The decisive disagreement across reports centers on terminal valuation multiples and the net cash conversion of the pipeline. Bullish perspectives argue that high-barrier biologics command durable monopoly pricing power, propelling core operating margins above 32% and justifying a premium multiple near twenty-four times forward earnings. Conversely, skeptical analyses emphasize that statutory price negotiations, partnered profit splits, and relentless clinical capital intensity will cap free cash flow yield near 3.5%, holding terminal multiples down around eighteen times. Resolving this tension requires tracking whether reported free cash flow accelerates alongside core operating earnings through 2027.
AstraZeneca: Critical Influencing Factors
Near-certain positive forcesTop Drivers & Tailwinds
Near-certain forces that support the investment thesis. These forces are treated as part of the base case (more than 60% probability of occurrence). Impact columns are specific to this asset class.
Scroll to view all columns
| Driver / Tailwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| Antibody conjugate and oncology expansion | Innovation And Product | +24% | +30% | Commercial scaling of Daiichi Sankyo-partnered antibody-drug conjugates, particularly Enhertu and datopotamab deruxtecan, drives robust volume expansion across early-line breast and lung cancers. Superior progression-free survival data secures high-margin treatment lines, replacing maturing revenue and insulating top-line growth from primary-care patent expirations over the forecast window. |
| Alexion rare disease cash compounding | Competitive Positioning | +15% | +18% | Patient migration from Soliris to long-acting Ultomiris alongside novel complement-inhibitor launches creates immense switching barriers in paroxysmal nocturnal hemoglobinuria. Inelastic therapeutic demand and orphan designations yield durable gross margins exceeding 85%, generating recurring operating cash flow that systematically funds late-stage pipeline investments without balance-sheet strain. |
| Respiratory biologic commercial lifecycle renewal | Innovation And Product | +14% | +16% | Phase III validation and regulatory submissions for tozorakimab in chronic obstructive pulmonary disease unlock a substantial addressable volume market across broad patient subgroups. Alongside Breztri and Tezspire, this portfolio renewal replaces expiring small-molecule inhaler revenues and preserves long-term specialty respiratory operating profitability. |
| Commercial infrastructure operating margin leverage | Operational Efficiency | +12% | +15% | Leveraging established global sales infrastructure allows specialty oncology and biologic launches to scale without proportional selling and administrative expense growth. Rationalized post-acquisition distribution and automated manufacturing compress unit overhead, supporting core operating margin progression toward low-thirties percentages and compounding per-share cash earnings. |
Near-certain negative forcesTop Frictions & Headwinds
Near-certain forces that could slow, cap, or damage the thesis. These forces are treated as part of the base case (more than 60% probability of occurrence). Impact columns are specific to this asset class.
Scroll to view all columns
| Friction / Headwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| Farxiga loss of exclusivity cliff | Sector And Industry | -15% | -18% | Loss of composition-of-matter patent protection on dapagliflozin across the United States and Europe triggers steep generic competition and rapid volume erosion. Stripping away an eight-billion-dollar high-margin pillar creates an acute earnings drag that requires substantial commercial contribution from newer therapies simply to stabilize segment profits. |
| Sovereign drug price negotiation compression | Regulatory | -11% | -13% | Implementation of mandatory Medicare maximum fair price negotiations under the Inflation Reduction Act alongside European reference pricing directly deflates net realized drug prices. Administrative pricing caps permanently truncate the tail-end cash flow of mature blockbusters, reducing terminal valuation multiples across AstraZeneca's primary geographic markets. |
| China regulatory scrutiny and procurement | Political And Geopolitical | -9.0% | -11% | Heightened legal oversight, executive indictments, and expanded Volume-Based Procurement in China suppress realized hospital margins across a market generating over 12% of revenue. Compulsory price reductions on off-patent portfolios and elevated local compliance costs dampen regional return on capital and slow international growth momentum. |
| Elevated clinical trial capital absorption | Capital Allocation | -8.0% | -9.0% | Sustaining over one hundred Phase III trials drives annual research and development spending above fourteen billion dollars, consuming roughly a quarter of sales. Escalating developmental complexity and clinical trial inflation dilute near-term free cash flow conversion, restricting aggressive share repurchase capacity and dividend expansion. |
AstraZeneca: What Could Break or Accelerate the Thesis
Event Risk Score: Very Low 18/100Asset-level relative pressure from clustered consensus frictions and tail risks. This is not the probability or risk score of an individual force.Plausible downside scenariosTail Risks
Tail yet plausible downside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Why plausible / what changes |
|---|---|---|---|
| Severe ADC interstitial lung toxicity crisis | 24% | -23% | Unexpected clustering of drug-related interstitial lung disease or severe off-target toxicities in pivotal Phase III trials by 2027 could prompt regulatory clinical holds or black-box warnings. Such safety setbacks would immediately curtail prescribing adoption in earlier-line settings, vaporizing billions in projected peak oncology cash flows and triggering significant multiple contraction. |
| China systemic hospital procurement debarment | 20% | -20% | Escalation of Chinese criminal probes into formal corporate sanctions, severe financial penalties, or exclusion from the National Reimbursement Drug List by 2027 would sever major emerging-market revenues. Losing unencumbered hospital market access across China would strand local capital infrastructure, impair consolidated operating profits, and inflict severe structural multiple compression. |
Plausible upside scenariosTail Opportunities
Tail yet plausible upside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Why plausible / what changes |
|---|---|---|---|
| Oral GLP1 cardiometabolic registrational triumph | 30% | +24% | Phase III clinical validation of oral GLP-1 candidate elecoglipron demonstrating weight-loss efficacy and tolerability comparable to injectable peptides by 2028 would crack the massive metabolic market. Bypassing cold-chain manufacturing bottlenecks would generate billions in high-margin peak revenue, expanding cardiometabolic earnings and triggering aggressive multiple rerating across global desks. |
| Frontline pan tumor ADC standard displacement | 32% | +20% | Accelerated registrational approvals establishing datopotamab deruxtecan and next-generation bispecifics as unconstrained first-line standards of care in lung and breast cancer by 2028 would broadly displace conventional chemotherapy. Expanding into frontline populations would multiply peak sales forecasts, driving substantial high-margin alliance royalties and expanding group operating margins. |
Company Financial AnalysisAstraZeneca: Earnings and Financials Analysis by AI
Financial figures available as of Sep 20, 2026. Only filings and source records available by this analysis date are included. View latest AstraZeneca financials here.
Earnings and financials
AstraZeneca's financial trajectory highlights a strong underlying commercial engine transitioning toward high-margin specialty medicine. Fiscal 2025 revenue rose 11% to USD 58.7 billion, and net income reached USD 10.22 billion, supported by robust oncology and rare-disease demand. Trailing twelve-month revenue expanded past USD 61 billion by mid-2026, demonstrating that double-digit volume growth in key cancer therapies has effectively cushioned early pricing pressures on mature cardiovascular lines. However, the composition of these earnings demands careful interpretation. While management's core operating metrics showcase double-digit expansion, reported statutory earnings reflect substantial charges for intangible asset amortization and legal provisions. Free cash flow generation of USD 8.43 billion remains solid, but cash conversion lags adjusted accounting profit due to ongoing launch investments and working capital movements.
Revenue, earnings, and cash flow
The table compares up to five fiscal years of revenue, net income, and free cash flow available to this analysis.
| Fiscal year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | USD 58.7B | USD 10.2B | USD 8.7B |
| 2024 | USD 52.9B | USD 6.9B | USD 7.3B |
| 2023 | USD 46.6B | USD 6.1B | USD 6.6B |
| 2022 | USD 44.3B | USD 3.3B | USD 7.2B |
| 2021 | USD 37.1B | USD 109.9M | USD 3.8B |
Valuation context: historical P/E
The table compares up to five fiscal years of point-in-time valuation evidence available to this analysis.
| Fiscal year | P/E | Earnings basis | Currency basis | Ticker / reporting |
|---|---|---|---|---|
| 2025 | 28.3x | TTM | USD-normalized | GBX / USD |
| 2024 | 29.1x | TTM | USD-normalized | GBX / USD |
| 2023 | 35.2x | TTM | USD-normalized | GBX / USD |
| 2022 | 64.5x | Annual | USD-normalized | GBX / USD |
| 2021 | >100x | Annual | USD-normalized | GBX / USD |
P/E uses historical market capitalization and earnings known at each period. Cross-currency observations are normalized to USD using point-in-time FX rates.
Profitability and margins
Profitability trends showcase meaningful structural expansion as the product portfolio shifts toward advanced biologic therapies. Gross margins widened to 81.9% in fiscal 2025, driven by an increasing mix of high-value oncology and rare-disease medicines that carry superior pricing power. Operating margins reached 23.4%, held in check primarily by deliberate increases in late-stage clinical development expenditure rather than underlying operational inefficiency. Sustaining margin expansion toward management's targeted mid-thirties percentage range will face intermediate friction. As patent expirations on Farxiga erode high-margin metabolic sales and statutory US price negotiation caps realized pricing, product mix will encounter temporary drag. Long-term margin progression depends on whether commercial launch volumes can generate sufficient operating leverage across existing sales infrastructure to absorb fixed research overhead.
The table compares up to five fiscal years of operating income and reported profitability margins.
| Fiscal year | Operating income | Operating margin | Net margin |
|---|---|---|---|
| 2025 | USD 13.7B | 23.4% | 17.4% |
| 2024 | USD 12.5B | 23.7% | 13.0% |
| 2023 | USD 9.6B | 20.5% | 13.0% |
| 2022 | USD 5B | 11.4% | 7.4% |
| 2021 | USD 2.8B | 7.6% | 0.3% |
Balance sheet and leverage
AstraZeneca's balance sheet reflects steady post-acquisition deleveraging, with the debt-to-equity ratio moderating to 0.61 by fiscal 2025 as total equity expanded to USD 48.7 billion. Net debt stood near USD 26.9 billion through mid-2026, matched by strong operating earnings that provide comfortable interest coverage exceeding eight times. This financial profile ensures solid debt service capacity and preserves access to commercial credit lines. Nevertheless, headline leverage metrics conceal significant ongoing commitments. A substantial portion of the company's USD 114 billion in assets consists of acquired intangible assets that generate recurring non-cash amortization charges. Furthermore, multi-year clinical collaboration milestones and planned manufacturing localization outlays limit balance-sheet flexibility, meaning major debt-funded acquisitions or aggressive share buybacks remain unlikely over the near term.
The table compares up to five fiscal years of debt, liquidity, net cash or debt, and current-ratio evidence.
| Fiscal year | Total debt | Cash + short-term investments | Reported net cash / (debt) | Debt less (cash + short-term investments), calculated | Current ratio |
|---|---|---|---|---|---|
| 2025 | USD 29.6B | USD 5.7B | USD 23.9B net debt | USD 23.9B | 0.94x |
| 2024 | USD 30.1B | USD 5.6B | USD 24.6B net debt | USD 24.5B | 0.93x |
| 2023 | USD 28.4B | USD 5.9B | USD 22.6B net debt | USD 22.5B | 0.81x |
| 2022 | USD 29.1B | USD 6.2B | USD 23B net debt | USD 22.9B | 0.86x |
| 2021 | USD 30.7B | USD 6.4B | USD 24.4B net debt | USD 24.3B | 1.16x |
Reported net debt retains the source definition, which can deduct cash alone. Cash plus short-term investments is broader liquidity; the separately calculated column subtracts that full amount from total debt for the same fiscal period and currency. Reported net debt below zero is displayed as net cash. Current ratio is current assets divided by current liabilities.
Capex and investment intensity
Management maintains an aggressive reinvestment posture, committing USD 14.23 billion to research and development in fiscal 2025, which represents over 24% of annual revenue. Physical capital expenditure absorbed an additional 10% of sales, directed toward state-of-the-art biologics production and automated antibody-drug conjugate manufacturing facilities in Singapore and the United States. This heavy capital deployment prioritizes scientific leadership over short-term accounting optics. This spending intensity reflects the realities of modern biopharmaceutical replacement. Rather than underinvesting to flatter near-term margins, the enterprise is constructing proprietary manufacturing networks and advancing more than one hundred Phase III clinical programs. While this elevated burn rate constrains immediate free cash flow yield, it builds formidable technical barriers that protect long-term returns on invested capital from generic duplication.
The table compares up to five fiscal years of capital expenditure and research-and-development investment.
| Fiscal year | Capital expenditure | R&D spend |
|---|---|---|
| 2025 | USD 5.9B | USD 14.2B |
| 2024 | USD 4.6B | USD 12B |
| 2023 | USD 3.8B | USD 10.5B |
| 2022 | USD 2.6B | USD 9.6B |
| 2021 | USD 2.2B | USD 8.4B |
Behind the synthesisAstraZeneca: How Each Individual AI Forecaster Opinion Shapes the Global Consensus
This publication’s recorded synthesis allocated voting influence across 14 advisor opinions. The weights and rationales below are retained from that synthesis.
The synthesized evidence reveals a clear common pattern: strong organic growth in targeted oncology and rare diseases is colliding with immediate patent expiries on legacy small molecules, notably Farxiga. Multiple reports share the premise that next-generation biologics, particularly antibody-drug conjugates and respiratory therapies, will eventually restore double-digit earnings growth. However, several analyses uncritically project management's eighty-billion-dollar revenue target without discounting partner profit-sharing, statutory US price concessions, or rising clinical capital intensity. The strongest contrarian analyses demonstrate that free cash flow conversion materially lags core accounting profits due to heavy research reinvestment and manufacturing commitments. Factual scrutiny confirms that while commercial replacement velocity is robust, intermediate multiple compression is inevitable as sovereign payers enforce price caps. Consequently, relative weighting prioritizes reports grounded in primary regulatory filings, audited cash flows, and realistic margin structures over those relying on speculative multiple expansion.
All 14 opinions
Universal Investor AI
The Polymath
OpenAI GPT-6 Astra · 2026-09-03 releaseWeight: 11.1%
Distinguished by meticulous primary source verification, grounded balance-sheet reconciliation, and granular cash conversion tracking. Accurately decouples headline revenue targets from distributable cash flows while properly accounting for partner economics, US policy agreements, and capital deployment.
Universal Investor AI
The Polymath
Anthropic Claude Opus 5 · 2026-07-24 releaseWeight: 11.1%
Exhibits superior evidence quality by incorporating recent Phase III readouts, corporate disclosures, executive insider buying, and specific policy agreements. Accurately identifies the divergence between reported IFRS figures and core metrics, grounding cash flow expectations in empirical operational constraints.
Sherlock Holmes AI
The Whistleblower
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 8.3%
Delivers forensic scrutiny on the gap between core accounting adjustments and statutory cash generation. Accurately maps the timing friction between Farxiga patent cliffs and late-stage respiratory launches, establishing realistic intermediate multiple compression expectations.
Universal Investor AI
The Polymath
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 7.4%
Provides a balanced evaluation of antibody-drug conjugate scaling against Farxiga patent expiration. Demonstrates causal consistency across oncology replacement dynamics, though relies somewhat heavily on standard consensus operating leverage assumptions without fully addressing US pricing negotiation nuances.
Niccolo Machiavelli AI
The Insider
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 7.4%
Presents astute analysis of geopolitical positioning, US onshore manufacturing commitments, and executive share purchases. The contrarian perspective on primary listing arbitrage adds insight, though the trajectory relies on somewhat ambitious regulatory resolution speeds in key international markets.
Ray Dalio AI
The Strategist
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 7.4%
Applies a sound macroeconomic regime framework, evaluating stagflationary impacts and balance sheet deleveraging with solid discipline. Appropriately balances commercial pipeline productivity against discount rate pressures, presenting an economically consistent through-cycle compounding trajectory.
Warren Buffett AI
The Value Seeker
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 6.5%
Applies rigorous owner-earnings analysis to evaluate capital allocation and platform defensibility. However, its projections slightly underestimate the initial margin dilution caused by generic Farxiga entry and overstate the velocity of small-molecule revenue replacement over the near-term forecast horizon.
Michael Burry AI
The Vulture
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 6.5%
Maintains disciplined focus on return on invested capital and valuation multiple compression in an elevated interest rate environment. Correctly details patent cliff vulnerabilities, though errs toward an overly pessimistic view on total franchise revenue substitution.
Universal Investor AI
The Polymath
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 6.5%
Effectively tracks antibody-drug conjugate scaling and rare disease durability, articulating a credible path to core operating margin expansion. Its primary limitation is understating the duration of emerging-market pricing headwinds and commercial launch reinvestment demands.
Superintelligence AI
The Anthropologist
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 6.5%
Features robust integration of primary scientific literature and commercial rollout milestones. While its biological moat assessment is exemplary, the projected valuation multiple expansion outpaces realistic limits imposed by persistent sovereign healthcare cost-containment initiatives.
Superintelligence AI
The Anthropologist
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 5.6%
Offers a trenchant critique of valuation multiples and clinical risk, correctly highlighting demographic tailwinds against therapeutic replacement challenges. However, the path assumes an excessively steep near-term derating that discounts demonstrable commercial demand across established oncology lines.
Elon Musk AI
The Visionary
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 5.6%
Provides a valuable skeptical lens on capital intensity and pharmaceutical research treadmill mechanics. While its friction assessments regarding Chinese scrutiny and Farxiga erosion are sound, the model excessively penalizes long-term free cash flow generation from rare-disease assets.
Warren Buffett AI
The Value Seeker
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 5.6%
Articulates an excellent qualitative assessment of therapeutic pricing power and switching barriers within rare diseases. However, its valuation multiple path remains somewhat elevated, giving insufficient weight to near-term free cash flow absorption from heavy clinical trial commitments.
J.P. Morgan AI
The Titan
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 4.6%
Constructs an extensive pipeline inventory but suffers from overly aggressive multiple expansion assumptions and hyperbolic top-line compounding projections. Downweighted due to excessive optimism regarding simultaneous blockbusters and minimal allowance for standard biopharma clinical attrition.
References & Context
Research Provenance
Analysis generated by iPulse AI Engine v7 using recorded market data, operating under the editorial standards and supervision of Russlan Ramdowar, Editor-in-Chief.
External references below are sources recorded by the researcher agents for this AstraZeneca forecast batch.
Primary analysis inputs
- iPulse AI Multi-Agent Forecasts — independent analyst personas, model outputs, and consensus synthesis.
- iPulse AI Global Events Context — macroeconomic, geopolitical, regulatory, and industry-event context.
- Structured market history — prices, distributions, volatility, identifiers, and listing metadata.
- Company earnings and financial statements — revenue, profitability, balance-sheet, cash-flow, and investment trends.
- Researcher web evidence — public sources consulted to challenge and contextualize the forecast thesis.
Independent AI Advisor panel
- AI Advisors
- 14
- AI Researchers
- 11
- AI Thinkers
- 3
Sources retained from AI Researcher searches
Asset-specific · Researcher web29 available sources from this batch (58 recorded). The first 15 are shown below; expand to read the rest.
- Approval Letter_220359Orig1s000ltr.pdf accessdata.fda.gov
- Selected Drugs and Negotiated Prices | CMS cms.gov
- ASTRAZENECA PLC - Form 6-K - FY2026 sec.gov
- ASTRAZENECA PLC - Form 6-K - FY2026 sec.gov
- Fact Sheet: President Donald J. Trump Announces Second Deal to Bring Most-Favored-Nation Pricing to American Patients whitehouse.gov
- AstraZeneca stock gains as Enhertu lung-cancer data offsets SERENA-4 setback ad-hoc-news.de
- AstraZeneca stock gains despite pipeline setbacks and YTD underperformance ad-hoc-news.de
- AstraZeneca stock gains on Goldman Sachs target rise ad-hoc-news.de
- Annual report 2025 astrazeneca.com
- AstraZeneca announces historic agreement with US Government to lower the cost of medicines for American patients astrazeneca.com
- AstraZeneca begins trading on the New York Stock Exchange astrazeneca.com
- AstraZeneca plans to invest $50 billion in America for medicines manufacturing and R&D astrazeneca.com
- Baxfendy approved in the US as the first and only aldosterone synthase inhibitor treatment for adults with hypertension astrazeneca.com
- Enhertu plus pertuzumab approved in the EU as first new regimen in more than a decade for the 1st-line treatment of patients with HER2-positive metastatic breast cancer astrazeneca.com
- H1 and Q2 2026 results astrazeneca.com
Show 14 more sources
- https://www.astrazeneca.com/content/dam/az/Investor_Relations/annual-report-2025/pdf/AstraZeneca_AR_2025_Financial_Statements.pdf astrazeneca.com
- https://www.astrazeneca.com/content/dam/az/PDF/2026/h1q2/H1-and-Q2-2026-results-announcement.pdf astrazeneca.com
- Search Results astrazeneca.com
- AstraZeneca (AZN) Stock Gains Momentum Following CEO Share Purchase and European Drug Approval bitcoinethereumnews.com
- AstraZeneca results: H1 and Q2 2026 businesswire.com
- Eplontersen trial did not meet its primary endpoint in transthyretin-mediated amyloid cardiomyopathy escardio.org
- AstraZeneca (AZN)’s Lung Drug Delivers the Good News its Pipeline Needed finance.yahoo.com
- AstraZeneca results: H1 and Q2 2026 finance.yahoo.com
- Update on CARDIO-TTRansform Phase 3 trial of eplontersen in adults with transthyretin-mediated amyloid cardiomyopathy | Ionis Pharmaceuticals, Inc. ir.ionis.com
- Pharmaceutical Policy in Motion: Updates on the Trump Administration’s Drug Pricing Initiatives | Mintz mintz.com
- AstraZeneca results: H1 and Q2 2026 | Nasdaq nasdaq.com
- Roundup: Every Most Favored Nation Agreement With the Trump Administration | Pharmacy Times pharmacytimes.com
- AstraZeneca CEO Pascal Soriot Buys 60,000 Company Shares - TipRanks.com tipranks.com
- REG - AstraZeneca PLC - Director/PDMR Shareholding — TradingView News tradingview.com
29 additional sources are recorded in this batch; their citation details are not available in this publication.
Context retained with this Consensus
The same public-safe market, global-event, and fundamental context supplied to the AI Advisor panel.
Global context snapshot
2025 Full-Year Global Market and World-Events Context
Download Archived SnapshotCoverage 2025-01-01 to 2025-12-31 · Knowledge cutoff 2025-12-31
This full-year context package covers the principal geopolitical, economic, monetary-policy, technology, trade, energy, and institutional developments that shaped global markets during 2025. It gives the forecasting model a chronological account of major world events together with their likely transmission into growth, inflation, interest rates, supply chains, commodities, currencies, public markets, and sector-level investment conditions.
Archived context covering 2025-01-01 to 2025-12-31. Its recorded scope includes technology and capital cycle; trade and industrial policy; monetary policy. Selected highlights reflect the analysis cutoff, not current world conditions.
Show moreShow less
- File size
- 90.8K bytes
- Words
- 13.3K words
- Characters
- 90.8K characters
- Est. tokens (characters ÷ 4)
- 22.7K tokens
The package also includes monthly and quarterly macroeconomic and cross-asset reference tables spanning US and international growth, central-bank policy, sovereign yields, major equity indices, foreign exchange, energy, industrial and precious metals, and digital assets. Quarterly and full-year high-impact summaries are integrated; monthly quantitative series remain working values pending final audit, and that qualification is part of the preserved context.
| Selected highlights from this archived snapshot | Date | Status |
|---|---|---|
| DeepSeek shock and AI economics reset | 2025-01-27 | OPEN ENDED TREND |
| US tariff regime escalation and trade-system rupture | 2025-02-01 | ACTIVE POLICY REGIME |
| Federal Reserve easing cycle after a prolonged hold | 2025-09-17 | ACTIVE POLICY REGIME |
Representative Sources of the Context File
And more sources from the retained context package.
2026 Year-to-Date Global Market and World-Events Context Through September 20
Download Archived SnapshotCoverage 2026-01-01 to 2026-09-20 · Knowledge cutoff 2026-09-20
January 1-September 20, 2026: monetary tightening, energy security, trade restrictions, AI financing and divergent growth; five leading market themes.
Archived context covering 2026-01-01 to 2026-09-20. Its recorded scope includes monetary policy and rates; geopolitics energy and shipping; trade and industrial policy. Selected highlights reflect the analysis cutoff, not current world conditions.
Show moreShow less
- File size
- 84.8K bytes
- Words
- 12.4K words
- Characters
- 84.8K characters
- Est. tokens (characters ÷ 4)
- 21.2K tokens
Fed raised rates to 3.75%-4.00%; ECB hike is in force and BOJ increase starts September 24. Markets through September 18, bitcoin through September 19.
| Selected highlights from this archived snapshot | Date | Status |
|---|---|---|
| Renewed monetary tightening amid persistent inflation | 2026-01-30 | ACTIVE POLICY REGIME |
| Iran/Hormuz conflict and wider energy-security disruption | 2026-02-28 | ONGOING |
| Tariff legal reset and strategic supply restrictions | 2026-02-20 | ACTIVE POLICY REGIME |
Representative Sources of the Context File
And more sources from the retained context package.
Fundamental Context Passed as Input to the Models
Time range: Annual fiscal periods: 2014-12-31–2025-12-31, 12 periods; Quarterly fiscal periods: 2023-12-31–2026-06-30, 12 periods.
Currencies cited: GBP, GBX, USD (quote GBX; primary reporting USD; converted/valuation USD; normalization GBP).
Show moreShow less
Income statement
9 fieldsdepreciationAndAmortization · ebit · ebitda · grossProfit · +5 more fields
Balance sheet
12 fieldscash · commonStockSharesOutstanding · longTermDebt · netDebt · +8 more fields
Cash flow
5 fieldscapitalExpenditures · dividendsPaid · freeCashFlow · salePurchaseOfStock · +1 more field
End of the paywalled preview
The excerpt from Deep Dive: detailed analysis to this notice is the simplified paywalled content included on this page. A signed-in, verified account with the required subscription provides the full interactive interface and the additional research, datasets and tools listed below.
Those additional materials are not included in this preview and cannot be revealed by removing its visual restrictions.
Additional with full access
Individual AI Advisor reports
- Investment theses
- Bull and bear scenarios and alpha signals
- Drivers, headwinds, risks and opportunities
- Quarterly forecast rationale
- Advisor research references and configuration
Additional datasets and interactive tools
- Interactive forecast comparisons
- Available detailed financial statements
- Market history and corporate-action adjustments
- Eligible historical publication workspaces
Explore complete public research examples
These public assets show the complete AI Consensus research. Their findings concern those assets, not this report.